Kenza Health Hub logoGet Started
1 May 2026Oral drugsSource update: September 2023

Sofosbuvir/Daclatasvir = SOF/DCV oral

Sofosbuvir and daclatasvir guidance for chronic hepatitis C across several genotypes and cirrhosis states.

Prescription under medical supervision
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Combination of two direct-acting antivirals: a NS5B polymerase inhibitor (sofosbuvir) and a NS5A inhibitor (daclatasvir).

Indications

Treatment of chronic hepatitis C.

Forms and strengths

  • 400 mg sofosbuvir/60 mg daclatasvir co-formulated tablet.

Dose and duration

Genotypes 1, 2, 4, 5, 6 without cirrhosis or with compensated cirrhosis and genotype 3 without cirrhosis

  • Adult: one 400 mg/60 mg tablet once daily for 12 weeks.

Genotype 3 with compensated cirrhosis or genotypes 1, 2, 3, 4, 5, 6 with decompensated cirrhosis

  • Adult: one 400 mg/60 mg tablet once daily for 24 weeks.

Contra-indications, adverse effects, precautions

  • Do not administer to patients with allergy to sofosbuvir or daclatasvir.
  • May cause fatigue, headache, insomnia, dizziness, gastrointestinal disturbances, and arthralgia.
  • Administer with caution to patients co-infected with hepatitis B virus because of the risk of HBV reactivation.
  • Do not combine with carbamazepine, phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, oral or injectable dexamethasone, or amiodarone.
  • Administer with caution and monitor combination with efavirenz, etravirine, nevirapine, clarithromycin, erythromycin, itraconazole, atazanavir/ritonavir, and digoxin.
  • Closely monitor blood glucose levels in patients with diabetes and adjust antidiabetic treatment if necessary.
  • Provide effective contraception in women of childbearing age.
  • Pregnancy and breast-feeding: contraindicated because safety is not established.
  • Tablets have a bitter taste and should be swallowed whole with meals.

Source

MSF Essential drugs practical guidelines (January 2026)

This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.

Rate this guide

Be the first to rate this guide.